Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its popular weight-loss drugs Mounjaro and Zepbound,.

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, respectively.

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in a trial, the company said on Tuesday.

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data show.